In This Section

Program

FRIDAY, OCTOBER 16, 2020

Saturday, October 17, 2020

Sunday, October 18, 2020

Monday, October 19, 2020

FRIDAY, OCTOBER 16, 2020

OPENING REMARKS AND OPENING KEYNOTES
5-7 P.M.

A case for priming, not checkpoint
Robert H. Vonderheide, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania

Clinical development of BCMA-directed therapies in multiple myeloma
Kristen M. Hege, Celgene Corporation, San Francisco, California

Opening Reception
7-9 P.M.

Saturday, October 17, 2020

Continental Breakfast
7-8 A.M.
Plenary Session 1: Synthetic Biology and Novel Approaches to Immune Engineering
8-10 A.M.         

Engineering artificial Antigen Presenting Complexes, aAPC, for cancer immunotherapy: From bench to bedside
Jonathan P. Schneck, Johns Hopkins University School of Medicine, Baltimore, Maryland

Title to be announced
Pamela A. Silver, Harvard Medical School, Boston, Massachusetts

 Additional speaker to be announced

Break
10-10:30 A.M.
Plenary Session 2: Vaccines, Neoantigens, and Oncolytic Viruses
10:30 A.M.-12:30 P.M.      

Building improved personal cancer vaccines
Catherine J. Wu, Dana-Farber Cancer Institute, Boston, Massachusetts

Title to be announced
Adrian Hill, Jenner Institute at Oxford University, Oxford, England

Additional speaker to be announced

Poster Session A/Lunch
12:30-3 P.M.
Networking Event
3-4 P.M.

Timothy A. Chan, Memorial Sloan Kettering Cancer Center, New York, New York

Keynote Presentation
4-5 P.M.

Speaker to be announced

Evening on own
5 P.M.

Sunday, October 18, 2020

Continental Breakfast
7-8 A.M.
Plenary Session 3: T-Cell Therapies
8-10 A.M.

Title to be announced
Marcela V. Maus, Massachusetts General Hospital, Boston, Massachusetts

Title to be announced
Avery D. Posey, University of Pennsylvania, Philadelphia, Pennsylvania

CARs and armoured CARs
Renier J. Brentjens, Memorial Sloan Kettering Cancer Institute, New York, New York

Break
10-10:30 A.M.
Plenary Session 4: Non-T-Cell Therapies
10:30 A.M.-12:30 P.M.

Title to be announced
Adrian C. Hayday, The Francis Crick Institute, London, England

Title to be announced
Judith Agudo, Dana-Farber Cancer Institute, Boston, Massachusetts

Title to be announced
Elizabeth J. Shpall, MD Anderson Cancer Center, Houston, Texas

Lunch on Own
12:30-2:30 P.M.
Plenary Session 5: Novel Combinations
2:30-4:30 P.M.

Title to be announced
Charles G. Drake, Columbia University Irving Medical Center, New York, New York

The QuEST for an effective immunotherapy for prostate cancer
James L. Gulley, National Cancer Institute, Bethesda, Maryland

Additional speaker to be announced

Poster Session B/Reception
4:30-7 P.M.

Monday, October 19, 2020

Continental Breakfast
7-8 A.M.
Plenary Session 6: Innate and Adaptive Checkpoints
8-10 A.M.

Targeting macrophages to promote anti-tumor immunity
Judith A. Varner, UCSD Moores Cancer Center, San Diego, California

Innate immune defenses against cancer: Potential for mobilizing NK cells for cancer immunotherapy
David H. Raulet, University of California, Berkeley, Berkeley, California

Additional speaker to be announced

Break
10-10:30 A.M.
Plenary Session 7: Defining Novel Immunotherapy Targets
10:30 A.M.-12:30 P.M.

Probing the immune system in cancer
Stephen J. Elledge, Harvard Medical School, Boston, Massachusetts

Title to be announced
Arlene H. Sharpe, Harvard Medical School, Boston, Massachusetts

Title to be announced
Peter A. Sims, Columbia University Herbert Irving Comprehensive Cancer Center, New York, New York

Closing remarks
12:30 P.M.